Subsequent to the in vitro investigations, the anti-angiogenic effect of anti-VEGF and anti-CD31 developed ITZ-siRNAVEGF NPs was investigated in the 4T1 breast cancer-bearing mice to study the in vivo angiogenesis suppression. This evidence concerns the gene VEGFA and breast carcinoma.